September 12, 2006 / Research Triangle Park, NC — Clinipace, Inc., a software company focused on late-stage clinical research studies and registries today announced its latest biotechnology client – Banyan Biomarkers, based in Alachua, Florida.
Through a grant provided by the United States Department of Defense, Banyan Biomarkers will seek to identify and validate biochemical substances (biomarkers) in the blood and cerebrospinal fluid of traumatic brain injury (TBI) patients that have potential utility in the diagnosis of injury severity, evaluation of treatment options, and assessment of treatment outcomes. It has been shown that biomarkers are released into the patient’s bloodstream after a head injury and that with the development of new diagnostic tools, identifying the presence of specific biomarkers can facilitate a timelier diagnosis and treatment plan for injuries sustained in military combat.
Nearly half of all combat deaths result from injuries to the head, and these injuries are among the most frequent causes of persistent disability for survivors. Additionally, exposure of military personnel to blast injuries from improvised explosive devices in Iraq has greatly increased the incidence of mild and moderate brain injuries which are challenging to diagnose and difficult to differentiate from other injuries such as shock or post traumatic stress syndrome. The findings from this research can also be applied to the management of civilian accidents.
Gary Ascani, Chief Executive Officer of Banyan Biomarkers talks about his company’s enthusiasm to begin the data collection: “After years of biomarker research and project planning, we are eager to begin the study’s data collection and analysis. We are pleased to be working with Clinipace on this endeavor and feel that their technology, Tempo, is the best choice for us as it is web-based, seamlessly supports our international research sites, and executes the data capture side of the study while managing the study itself.”
Banyan Biomarkers has selected Clinipace’s technology to play the important role of capturing and managing the clinical data collected at several sites within the United States and Europe over a three-year period. With Clinipace’s clinical trial solution Tempo, an easy-to-use, web-based software platform that supports the two core functional needs of clinical studies, Clinical Data Capture and Study Management, within a single platform, companies like Banyan Biomarkers can accelerate time to study-start, and focus on their research – not on the development and management of technology.
“We are particularly proud of supporting Banyan Biomarkers in this work as the results of their study may translate into faster and better medical treatment for our injured soldiers. This is important research and we are pleased Banyan has placed their faith in us to help them conduct it,” commented Jeff Williams, Chief Executive Officer of Clinipace.
More than 1.5 million people annually suffer TBI in the U.S. resulting in more than 230,000 hospitalizations, 50,000 deaths and 80,000 disabilities. TBI is the greatest cause of disability in young people under 24 years old. Currently, 5.3 million Americans live with TBI-related disabilities. The accurate diagnosis in acute care environments can significantly simplify decisions about patient management – improving patients’ outcomes.
About Banyan Biomarkers
Founded in collaboration with the University of Florida in March 2002 as Daimonion Diagnostics, LLC, the company was incorporated and renamed Banyan Biomarkers Inc. in January 2004. Through contractual arrangements with the University of Florida, Banyan investigators capitalize on the world renowned facilities at the university’s Evelyn F. and William McKnight Brain Institute. More information on the Company can be found at http://www.banyanbio.com.
Clinipace is a clinical research software company providing a single, integrated data capture and study management platform for post-approval research and registries conducted by biopharmaceutical and medical device companies, Clinical Research Organizations (CROs) and Academic Medical Centers (AMCs). Our platform, called Tempo, is delivered via a web-based, on-demand architecture that streamlines the clinical research process by eliminating the integration headaches associated with multiple platforms, reducing project efforts and costs from startup to conclusion, and empowering project stakeholders to make informed real-time decisions regarding their research. For more information on Clinipace, please visit: www.clinipace.com.